PUBLISHER: The Business Research Company | PRODUCT CODE: 1945400
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945400
Interventional oncology devices are specialized medical tools and technologies designed for the minimally invasive diagnosis and treatment of cancer. These devices enable direct targeting of tumors, allowing for treatments such as ablation or embolization, which focus on destroying cancer cells while preserving nearby healthy tissue.
The primary products within the field of interventional oncology devices include embolization devices, ablation devices, and support devices. Embolization devices are designed for the embolization of blood vessels associated with various tumors. These devices are employed in procedures such as thermal tumor ablation, non-thermal tumor ablation, transcatheter arterial chemoembolization (TACE), transcatheter arterial radioembolization (TARE), selective internal radiation therapy (SIRT), and transcatheter arterial embolization (TAE) or bland embolization. These procedures are applied in the treatment of various cancer types, including liver cancer, kidney cancer, lung cancer, bone cancer, and others.
Tariffs are influencing the interventional oncology devices market by increasing costs of imported imaging systems, ablation probes, catheters, embolic materials, and electronic control components. Oncology centers and hospitals in North America and Europe are most affected due to reliance on specialized imported devices, while Asia-Pacific faces cost pressure on device manufacturing and exports. These tariffs are increasing capital expenditure for cancer treatment facilities. However, they are also encouraging domestic device innovation, regional manufacturing expansion, and localized supply chain development for oncology technologies.
The interventional oncology devices market research report is one of a series of new reports from The Business Research Company that provides interventional oncology devices market statistics, including interventional oncology devices industry global market size, regional shares, competitors with a interventional oncology devices market share, detailed interventional oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology devices industry. This interventional oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The interventional oncology devices market size has grown strongly in recent years. It will grow from $2.5 billion in 2025 to $2.68 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing cancer incidence rates, expansion of interventional radiology practices, improvements in imaging technologies, growing adoption of minimally invasive oncology treatments, availability of specialized oncology centers.
The interventional oncology devices market size is expected to see strong growth in the next few years. It will grow to $3.5 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing demand for targeted cancer therapies, rising investments in precision oncology, expansion of outpatient cancer treatment settings, growing adoption of combination interventional therapies, technological advancements in ablation and embolization devices. Major trends in the forecast period include increasing adoption of image-guided tumor ablation devices, rising use of minimally invasive cancer treatments, growing deployment of embolization therapies, expansion of precision oncology procedures, enhanced integration of advanced imaging support systems.
The high prevalence of cancer is anticipated to drive the growth of the interventional oncology devices market in the coming years. Cancer refers to a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body. These abnormal cells can form masses or tumors. The increasing prevalence of cancer raises the demand for interventional oncology devices, as they are used for the diagnosis, treatment, and management of cancer, supporting early detection, staging, and ongoing monitoring. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, the number of cancer cases diagnosed in Australia rose from 160,570 in 2022 to 164,694 in 2023, indicating a notable year-on-year increase. This upward trend underscores the growing prevalence of cancer in the country. Therefore, the high prevalence of cancer is contributing to the growth of the interventional oncology devices market.
Leading players operating in the interventional oncology devices market are emphasizing advanced technologies, such as tissue volume, to improve diagnostic precision and treatment effectiveness in oncology procedures. Tissue volume refers to the quantity of biological tissue obtained during a biopsy procedure. Collecting larger tissue volumes enables more comprehensive samples, thereby enhancing diagnostic accuracy and the effectiveness of treatment planning. For instance, in June 2023, Argon Medical, a US-based medical device company, introduced the SuperCore Advantage semi-automatic biopsy device. The SuperCore Advantage is capable of collecting up to 35% more samples compared to leading competitors, reducing the need for multiple biopsy passes. This capability is essential for obtaining sufficient tissue samples to support accurate diagnosis.
In May 2024, Siemens Healthineers, a Germany-based provider of devices and imaging systems supporting interventional oncology, entered into a partnership with University Hospitals to advance precision care through innovation and integrated clinical excellence. The collaboration aims to improve oncology, cardiovascular, and neurovascular outcomes by jointly advancing theranostics, novel MR technologies, and next-generation patient care solutions. University Hospitals is a US-based healthcare system.
Major companies operating in the interventional oncology devices market are Boston Scientific Corporation, Terumo Corporation, Siemens Healthineers, Sirtex Medical Limited, AngioDynamics Inc., Viant Medical, Medtronic plc, Olympus Corporation, Koninklijke Philips, Quantum Surgical, Profound Medical, Intuitive Surgical Inc, Cook Medical LLC, EDAP TMS S.A, Varian Medical Systems Inc, Heraeus Medical, ABLbio, Bioavlee, Mediceena International, LifeTech Scientific Corporation
North America was the largest region in the interventional oncology devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the interventional oncology devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the interventional oncology devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The interventional oncology devices market consists of sales of embolization devices, ablation devices, and support devices. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Interventional Oncology Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses interventional oncology devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for interventional oncology devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The interventional oncology devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.